Potential role of MELD and MAP18 in patients with structural temporal lobe epilepsy

MELD评分和MAP18评分在结构性颞叶癫痫患者中的潜在作用

阅读:1

Abstract

PURPOSE: This study compared two image post-processing toolboxes primarily designed for focal cortical dysplasia (FCD): Multi-Centre Epilepsy Lesion Detection (MELD) and Morphometric Analysis Program (MAP18), in identifying temporal lobe epilepsy (TLE) structural lesions on MRI. METHODS: This retrospective study examined 79 adults, 58 patients with confirmed TLE, and 21 healthy controls. All participants underwent an elective brain MRI between June 2007 - May 2023 at Hospital Clinic, Barcelona, Spain. All the 3D T1-weighted images were processed using MELD and MAP18 to detect potential epileptogenic lesions. The location (lateral or mesial) and laterality of the reference TLE structural lesion (refTLE) were determined through histopathology or multidisciplinary consensus based on clinical data. Toolboxes' performance was evaluated using descriptive statistics, specificity, and diagnostic accuracy. Additionally, a second-look MRI was conducted for cases where abnormalities detected by MELD and MAP18 did not match the refTLE. RESULTS: MELD and MAP18 demonstrated variability in specificity and diagnostic accuracy. Specificity ranged from 48% to 86%, with ProbMAP (MAP18) achieving the highest values. Global diagnostic accuracy ranged from 7% to 42%, with MELD showing the highest performance. In four patients with visible epileptogenic lesions on MRI, MELD and MAP18 identified additional abnormalities that were previously overlooked. Moreover, MELD detected one TLE lesion in one patient initially classified as MRI-negative (nonlesional). CONCLUSION: Incorporating tools like MELD and MAP18 into the diagnostic workflow can enhance the detection of TLE-related abnormalities on MRI, potentially improving patient outcomes and aiding in clinical decision-making.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。